Tag Archives: Neural Therapeutics

Toronto, Ontario–(Newsfile Corp. – June 6, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) (“Neural” or the “Company“), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. (“CWE“), operating as Hanf.com, one of the Germany’s …

Toronto, Ontario–(Newsfile Corp. – May 13, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) (“Neural” or the “Company”), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, announces that the Board of Directors approved the grant of 2,720,000 restricted share …

Toronto, Ontario–(Newsfile Corp. – May 9, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) (“Neural” or the “Company”), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to Servicio Nacional …

Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline Doses Extraction Technology Delivering Higher Yields and Greater Purity Frankfurt Stock Exchange Ticker Symbol Changed to “HANF” Extension of LOI with CWE European Holdings (dba Hanf.com) Toronto, Ontario–(Newsfile Corp. – April 14, 2025) – Neural Therapeutics Inc. …

Toronto, Ontario–(Newsfile Corp. – March 31, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on …

Toronto, Ontario–(Newsfile Corp. – March 17, 2025) – he Canadian Securities Exchange (“CSE” or “the Exchange”) today welcomed the listing of Neural Therapeutics Inc. (“Neural Therapeutics” or the “Company”). The Toronto-based company has completed a private placement financing, and its common shares have been approved for listing on the CSE …

Toronto, Ontario–(Newsfile Corp. – March 17, 2025) – Neural Therapeutics Inc. (CSE: NURL) (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that its common shares will commence trading on the Canadian Securities …

Toronto, Ontario–(Newsfile Corp. – Le 13 mars/March 2025) – The common shares of Neural Therapeutics Inc. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Neural Therapeutics is an ethnobotanical drug discovery company, focusing on the development of …

Toronto, Ontario–(Newsfile Corp. – March 13, 2025) – Neural Therapeutics Inc. (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has completed the final tranche of its previously announced private placement …